Abstract:Background Parvovirus B19-associated pure red cell aplasia (PVB19-PRCA) is an uncommon but serious complication after kidney transplantation. Currently, intravenous immunoglobulin (IVIG) is preferred as the first-line treatment for PVB19-PRCA, but presents with disadvantages of disease recurrence and expensive cost. In this context, we propose that foscarnet therapy for kidney transplantation recipients (KTR) with PVB19-PRCA may be an alternative scenario. No related study has been reported, and we performed this study to assess the efficacy and safety of foscarnet for PVB19-associated PRCA in KTR. Methods We conducted a retrospective review of PVB19-PRCA in KTR at our center over 9-year period. The data on therapy and outcomes in all cases treated with foscarnet are detailed records and summarized. Results Among our 68 patients, PVB19-PRCA was confirmed in 50 based on inclusion/exclusion criteria. All patients presented with refractory anemia and low reticulocyte percentage (<0.5%), the mean hemoglobin of patients was 79.8±12.6g/L at the time of PVB19-PRCA was identified. The median serum genome copy number of parvovirus B19 at diagnosis was 9.6 log10 copies per milliliter. A total of 11 patients received foscarnet therapy, of 10 patients responded well to the treatment and maintained no recurrence. But 1 patient had a poor response to foscarnet therapy. Except for this patient, the mean hemoglobin level gradually increased from 68.5±9.3 g/L to 73.2±8.8 g/L, and the mean percentage of reticulocytes steadily increased from 0.1±0.0% to 7.6±2.9% after foscarnet therapy. The median serum genome copy number of parvovirus B19 decreased from 9.8 log10 to 6.1 log10 copies per milliliter. There was no significant difference (P=0.61, 0.60) in serum creatinine and glomerular filtration rate before and after foscarnet treatment. At the latest follow-up, the mean hemoglobin was 131.5±12.5 g/L and the hemoglobin correction occurred in all patients. Conclusion Foscarnet therapy doesn't seem to be worse than IVIG for PVB19-PRCA in KTR, and it can be an alternative option.

Foscarnet Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection in Kidney Transplant Recipients: A Preliminary Exploration

Pure Red Cell Apalsia Caused by Infection of Human Parvovirus B19 Post-Renal Transplantation: 8 Cases Report and Review

FTY720 and Cyclosporin Protect Ovarian Tissue Grafted into Rabbits.

Immune Reconstitution and Survival of Patients with Parvovirus B19 Related Pure Red Cell Aplasia after Haplo-Pbsct

Managing recurrent parvovirus B19-associated anemia after a pediatric kidney transplant

Parvovirus B19 Infection due to over Immunosuppression in Kidney Transplant Recipients: Case Reports and Literature Review

Clinical utility of immune function based on IFN-γ monitoring of lymphocyte subsets for parvovirus B19 infection in renal recipients

Long‐term Remission of Recurrent Severe Anemia As a Result of Parvovirus B19 Infection in a Pediatric Renal Transplant Recipient

Donor-Derived Human Parvovirus B19 Infection in Kidney Transplantation

Human Parvovirus B19 Infection Induced Pure Red Cell Aplasia in Liver Transplant Recipients

Pure red cell aplasia due to parvovirus B19 infection in solid organ transplantation

Risk Factors and Treatment of Focal Segmental Glomerulosclerosis Recurrence in Renal Transplantation

The impact of intravenous methylprednisolone pulses on renal survival in anti-neutrophil cytoplasmic antibody associated vasculitis with severe renal injury patients: a retrospective study

The Detection, Treatment of Parvovirus B19 Infection Induced Anemia in Solid Organ Transplants: A Case Series and Literature Review of 194 Patients.

Dose‐by‐dose Virological and Hematological Responses to Intravenous Immunoglobulin in an Immunocompromised Patient with Persistent Parvovirus B19 Infection

TCRαβ-depleted Hematopoietic Stem Cell Transplant and Third-Party CD45RA+ Depleted Adoptive Cell Therapy for Treatment of Post-Transplant Parvovirus B19 Aplastic Crisis

Clinical Characteristics of Human Parvovirus B19 Infection after Allogeneic Stem Cell Transplantation

The Impact of Pretransplant Cytomegalovirus Infection on Acute Renal Allograft Rejection

The Successful Treatment of a Cord Blood Transplant Recipient with Varicella Zoster Virus Meningitis, Radiculitis and Myelitis with Foscarnet

Treatment Of Cytomegalovirus Infection After Renal Transplantation: Experience From A Single Center In China

Parvovirus B19 Infection in Kidney Transplant Recipients: A Prospective Study in a Teaching Hospital in Shanghai, China.